Expression and T cell regulatory action of the PD-1 immune checkpoint in the ovary and fallopian tube

被引:4
|
作者
Johnson, Joshua [1 ,2 ]
Kim, So-Youn [3 ]
Sam, Peter Ka [4 ]
Asokan, Rengasamy [1 ]
Cari, Evelyn Llerena [1 ,2 ]
Bales, Elise S. S. [1 ]
Luu, Thanh-Ha [1 ,2 ]
Perez, Lauren [5 ]
Kallen, Amanda N. N. [6 ]
Nel-Themaat, Liesl [2 ,7 ]
Polotsky, Alex J. J. [1 ,2 ,7 ]
Post, Miriam D. D. [8 ]
Orlicky, David J. J. [8 ]
Jordan, Kimberly R. R. [9 ]
Bitler, Benjamin G. G. [1 ]
机构
[1] Univ Colorado Anschutz Med Campus, Dept Obstet & Gynecol, Div Reprod Sci, Aurora, CO 80045 USA
[2] Dept Obstet & Gynecol, Div Reprod Endocrinol & Infertil, Aurora, CO USA
[3] Univ Nebraska Med Ctr, Coll Med, Olson Ctr Womens Hlth, Dept Obstet & Gynecol, Omaha, NE USA
[4] Univ Colorado Boulder, Boulder, CO USA
[5] Univ Calif Los Angeles, Los Angeles, CA USA
[6] Yale Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT USA
[7] Shady Grove Fertil Colorado, Denver, CO USA
[8] Univ Colorado Anschutz Med Campus, Dept Pathol, Aurora, CO USA
[9] Univ Colorado Anschutz Med Campus, Dept Immunol & Microbiol, Human Immunol & Immunotherapy Initiat, Human Immune Monitoring Shared Resource, Aurora, CO USA
关键词
autoimmunity; fallopian tube; fertility; immune checkpoints; ovarian cancer; ovary; PD-1; pathway; AUTOIMMUNE OOPHORITIS; SEROUS CARCINOMA; SPLICE VARIANTS; SOLUBLE PD-1; B7; FAMILY; IN-VITRO; CANCER; WOMEN; IMMUNOTHERAPY; STIMULATION;
D O I
10.1111/aji.13649
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
ProblemImmune cell trafficking and surveillance within the ovary and fallopian tube are thought to impact fertility and also tumorigenesis in those organs. However, little is known of how native cells of the ovary and fallopian tube interact with resident immune cells. Interaction of the Programmed Cell Death Protein-1 (PD-1/PDCD-1/CD279) checkpoint with PD-L1 is associated with downregulated immune response. We have begun to address the question of whether PD-1 ligand or its receptors (PD-L1/-L2) can regulate immune cell function in these tissues of the female reproductive tract. Method of studyPD-1 and ligand protein expression was evaluated in human ovary and fallopian tube specimens, the latter of which included stages of tubal cell transformation and early tumorigenesis. Ovarian expression analysis included the determination of the proteins in human follicular fluid (HFF) specimens collected during in vitro fertilization procedures. Finally, checkpoint bioactivity of HFF was determined by treatment of separately-isolated human T cells and the measurement of interferon gamma (IFN gamma). ResultsWe show that membrane bound and soluble variants of PD-1 and ligands are expressed by permanent constituent cell types of the human ovary and fallopian tube, including granulosa cells and oocytes. PD-1 and soluble ligands were present in HFF at bioactive levels that control T cell PD-1 activation and IFN gamma production; full-length checkpoint proteins were found to be highly enriched in HFF exosome fractions. ConclusionThe detection of PD-1 checkpoint proteins in the human ovary and fallopian tube suggests that the pathway is involved in immunomodulation during folliculogenesis, the window of ovulation, and subsequent egg and embryo immune-privilege. Immunomodulatory action of receptor and ligands in HFF exosomes is suggestive of an acute checkpoint role during ovulation. This is the first study in the role of PD-1 checkpoint proteins in human tubo-ovarian specimens and the first examination of its potential regulatory action in the contexts of normal and assisted reproduction.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Progress in understanding the regulatory mechanisms of immune checkpoint proteins PD-1 and PD-L1 expression
    Wu, Xuanxuan
    Zhu, Zengjun
    Zhang, Jian
    Tian, Maojin
    Zhao, Peiqing
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2025,
  • [2] PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance
    Tan, Catherine L.
    Kuchroo, Juhi R.
    Sage, Peter T.
    Liang, Dan
    Francisco, Loise M.
    Buck, Jessica
    Thaker, Youg Raj
    Zhang, Qianxia
    McArdel, Shannon L.
    Juneja, Vikram R.
    Lee, Sun Jung
    Lovitch, Scott B.
    Lian, Christine
    Murphy, George F.
    Blazar, Bruce R.
    Vignali, Dario A. A.
    Freeman, Gordon J.
    Sharpe, Arlene H.
    JOURNAL OF EXPERIMENTAL MEDICINE, 2021, 218 (01):
  • [3] Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses
    Liu, Jun
    Yuan, Ying
    Chen, Wenna
    Putra, Juan
    Suriawinata, Arief A.
    Schenk, Austin D.
    Miller, Halli E.
    Guleria, Indira
    Barth, Richard J.
    Huang, Yina H.
    Wang, Li
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2015, 112 (21) : 6682 - 6687
  • [4] The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint
    Wang, Qingshui
    Lin, Wei
    Tang, Xiaoqiong
    Li, Suhuan
    Guo, Libin
    Lin, Yao
    Kwok, Hang Fai
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (12)
  • [5] Macrocyclic Peptide Inhibitor of PD-1/PD-L1 Immune Checkpoint
    Magiera-Mularz, Katarzyna
    Kuska, Katarzyna
    Skalniak, Lukasz
    Grudnik, Przemyslaw
    Musielak, Bogdan
    Plewka, Jacek
    Kocik, Justyna
    Stec, Malgorzata
    Weglarczyk, Kazimierz
    Sala, Dominik
    Wladyka, Benedykt
    Siedlar, Maciej
    Holak, Tad A.
    Dubin, Grzegorz
    ADVANCED THERAPEUTICS, 2021, 4 (02)
  • [6] PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy
    Dermani, Fatemeh K.
    Samadi, Pouria
    Rahmani, Golebagh
    Kohlan, Alisa K.
    Najafi, Rezvan
    JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (02) : 1313 - 1325
  • [7] Pyrazolones as inhibitors of immune checkpoint blocking the PD-1/PD-L1 interaction
    Le Biannic, Raphael
    Magnez, Romain
    Klupsch, Frederique
    Leleu-Chavain, Natascha
    Thiroux, Bryan
    Tardy, Morgane
    El Bouazzati, Hassiba
    Dezitter, Xavier
    Renault, Nicolas
    Vergoten, Gerard
    Bailly, Christian
    Quesnel, Bruno
    Thuru, Xavier
    Millet, Regis
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 236
  • [8] Characterization of PD-1/PD-L1 immune checkpoint expression in the pathogenesis of musculoskeletal Langerhans cell histiocytosis A retrospective study
    Hashimoto, Kazuhiko
    Nishimura, Shunji
    Sakata, Naoki
    Inoue, Masami
    Sawada, Akihisa
    Akagi, Masao
    MEDICINE, 2021, 100 (43) : E27650
  • [9] Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
    Lipson, Evan J.
    Lilo, Mohammed T.
    Ogurtsova, Aleksandra
    Esandrio, Jessica
    Xu, Haiying
    Brothers, Patricia
    Schollenberger, Megan
    Sharfman, William H.
    Taube, Janis M.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [10] Neurological adverse events associated with PD-1/PD-L1 immune checkpoint inhibitors
    Zhou, Yanting
    Li, Hongyan
    FRONTIERS IN NEUROSCIENCE, 2023, 17